A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy.
In 1982-1984 we conducted a six-month clinical trial in 50 previously untreated lepromatous leprosy patients randomly assigned to directly observed monotherapy with one of two thioamides, ethionamide or prothionamide, each given six times a week at doses of either 250 mg or 500 mg. The findings of this study have only recently been analyzed, and the potential for the use of these thioamides in leprosy patients placed in perspective. However, because of the small number of patients included in this study, the results must be interpreted with some caution. Clinical improvement was noted in 74% of the patients treated with ethionamide and in 83% of those treated with prothionamide. Therapy was well tolerated and drug-related hepatotoxicity did not require discontinuation of therapy. The 500-mg dose of both ethionamide and prothionamide resulted in loss in Mycobacterium leprae viability more rapidly than did the 250-mg dose, and prothionamide at both dose levels was superior to the equivalent dose of ethionamide. Overall killing of M. leprae in this study was found to be similar to that obtained previously with dapsone and clofazimine, but less than was obtained with rifampin, minocycline, clarithromycin, pefloxacin, and ofloxacin.
Fajardo
Tranquilino T
TT
Leonard Wood Memorial Center for Leprosy Research, Cebu City, The Philippines.
Guinto
Ricardo S
RS
Cellona
Roland V
RV
Abalos
Rodolfo M
RM
Dela Cruz
Eduardo C
EC
Gelber
Robert H
RH
D000293:Adolescent; D000328:Adult; D000818:Animals; D001706:Biopsy; D002648:Child; D004305:Dose-Response Relationship, Drug; D005000:Ethionamide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007917:Leprostatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015440:Leprosy, Lepromatous / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008875:Middle Aged; D009166:Mycobacterium leprae / Q000254:growth & development*; D011515:Prothionamide / Q000009:adverse effects / Q000627:therapeutic use*
D007917:Leprostatic Agents; D011515:Prothionamide; D005000:Ethionamide